Puma Biotechnology (NASDAQ:PBYI) Releases Earnings Results, Beats Expectations By $0.09 EPS

Puma Biotechnology (NASDAQ:PBYI) released its earnings results on Thursday. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.09, FiscalAI reports. Puma Biotechnology had a return on equity of 20.81% and a net margin of 10.69%.The company had revenue of $44.81 million during the quarter, compared to analyst estimates of $42.00 million.

Here are the key takeaways from Puma Biotechnology’s conference call:

• ALISCA‑Lung1 interim: higher‑dose alisertib (60 mg) showed a median PFS of 4.2 months versus 1.7 months at 50 mg and activity is enriched in c‑MYC‑high tumors; dose escalation to 70 mg and a combination ALISCA‑Lung2 (with paclitaxel) are planned for H2 2026.
• ALISCA‑Breast1 interim: alisertib plus endocrine therapy showed median PFS ~5.45–5.59 months in the 40–50 mg arms with stronger efficacy in biomarker subgroups (PIK3CA wild‑type, ESR1‑mutant and high c‑MYC); enrollment will be expanded to biomarker‑focused cohorts and updated data are expected H2 2026.
• Financials & guidance: raised FY2026 net NERLYNX product revenue guidance to $202–206M, expects FY net income of $16–19M, and is now debt‑free after the final Athyrium payment with ~$101.5M in cash/marketable securities as of 3/31/2026.
• Q1 commercial softness: Q1 net product revenue fell to $42.0M (2,328 ex‑factory bottles, down ~29% QoQ) driven in part by an estimated ~439‑bottle inventory drawdown at specialty channels; TRXs were down ~4% QoQ and demand declined ~6% QoQ despite higher NRX and enrollment trends.

Puma Biotechnology Price Performance

PBYI traded up $0.23 during midday trading on Friday, reaching $7.49. 755,011 shares of the company’s stock traded hands, compared to its average volume of 267,164. The firm has a fifty day moving average of $6.81 and a two-hundred day moving average of $6.19. The stock has a market capitalization of $381.17 million, a price-to-earnings ratio of 15.60 and a beta of 1.24. Puma Biotechnology has a 52 week low of $2.85 and a 52 week high of $7.90.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PBYI. Cerity Partners LLC bought a new position in Puma Biotechnology during the 2nd quarter valued at approximately $36,000. BNP Paribas Financial Markets raised its position in Puma Biotechnology by 39.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 2,290 shares during the last quarter. Abel Hall LLC bought a new position in Puma Biotechnology during the 4th quarter valued at approximately $64,000. Dynamic Technology Lab Private Ltd bought a new position in Puma Biotechnology during the 1st quarter valued at approximately $66,000. Finally, Ieq Capital LLC bought a new position in Puma Biotechnology during the 4th quarter valued at approximately $68,000. Institutional investors own 61.29% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on PBYI shares. Wall Street Zen raised Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 21st. Weiss Ratings reissued a “hold (c+)” rating on shares of Puma Biotechnology in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Puma Biotechnology presently has a consensus rating of “Hold”.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.